A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to compare the safety and efficacy of Tafasitamab with BEN versus RTX with BEN in adult patients with relapsed of refractory DLBCL.

Detailed Description
-----------------
This is a randomised, two-arm, multicentre, open-label phase II/III efficacy and safety study of Tafasitamab in combination with BEN versus RTX in combination with BEN given to adult patients who have relapsed after or are refractory to at least one but no more than three prior systemic therapies and have failed, or are not candidates for HDC and ASCT, and have thus exhausted their therapeutic options of demonstrated clinical benefit. At least one prior therapy line must have included a CD20-targeted therapy.

Official Title
-----------------
A Phase 2/3, Randomised, Multicentre Study of Tafasitamab With Bendamustine Versus Rituximab With Bendamustine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL) Who Are Not Eligible for High-Dose Chemotherapy (HDC) and Autologous Stem-Cell Transplantation (ASCT)

Conditions
-----------------
Diffuse Large B-cell Lymphoma

Intervention / Treatment
-----------------
* Drug: Rituximab (RTX)
* Drug: Tafasitamab
* Drug: Bendamustine (BEN)


Participation Criteria
=================
Eligibility Criteria
-----------------
INCLUSION CRITERIA: Age ≥18 years Histologically confirmed diagnosis, according to the World Health Organization (WHO, 2008) classification, of: DLBCL NOS, THRLBCL, EBV-positive DLBCL, composite lymphoma with a DLBCL component with a DLBCL relapse subsequent to DLBCL treatment, disease transformed from an earlier diagnosis of low grade lymphoma (i.e. an indolent pathology such as follicular lymphoma, marginal zone lymphoma) into DLBCL with a DLBCL relapse subsequent to DLBCL treatment. Fresh tumour tissue for central pathology review must be provided as an adjunct to participation in this study. Should it not be possible to obtain a fresh tumour tissue sample, archival paraffin embedded tumour tissue acquired ≤3 years prior to screening for this protocol must be available for this purpose. Patients must have: relapsed or refractory DLBCL at least one bidimensionally measurable disease site. The lesion must have a greatest transverse diameter of ≥1.5 cm and greatest perpendicular diameter of ≥1.0 cm at baseline. The lesion must be positive on PET scan received at least one, but no more than three previous systemic therapy lines for the treatment of DLBCL. At least one previous therapy line must have included a CD20-targeted. ECOG 0 to 2 Patients after failure of ASCT or patients considered in the opinion of the investigator currently not eligible for HDC with subsequent ASCT. Patients must meet the following laboratory criteria at Screening: ANC ≥1.5 × 109/L (unless secondary to bone marrow involvement by DLBCL) PLTs ≥90 × 109/L (unless secondary to bone marrow involvement by DLBCL) and absence of active bleeding total serum bilirubin ≤2.5 × ULN unless secondary to Gilbert's syndrome (or pattern consistent with Gilbert's) or documented liver involvement by lymphoma. Patients with Gilbert's syndrome or documented liver involvement by lymphoma may be included if their total bilirubin is ≤5 x ULN ALT, AST and AP ≤3 × ULN or <5 × ULN in cases of documented liver involvement by lymphoma serum creatinine ≤2.0 x ULN or creatinine clearance must be ≥40 mL/min calculated using a standard Cockcroft-Gault formula (Cockroft & Gault, 1976) For a female of childbearing potential (FCBP), a negative pregnancy test must be confirmed before enrolment. An FCBP must commit to take highly effective contraceptive precautions without interruption during the study and for 3, 6 or 12 months after the last dose of Tafasitamab, BEN or RTX respectively, whichever is later. An FCBP must refrain from breastfeeding and donating blood or oocytes during the course of the study and for 3, 6 or 12 months after the last dose of Tafasitamab, BEN or RTX respectively, whichever is later. Restrictions concerning blood donations apply as well to females who are not of childbearing potential. Males must use an effective barrier method of contraception without interruption during the study and for 3, 6 or 12 months after the last dose of Tafasitamab, BEN or RTX respectively, whichever is later, if the patient is sexually active with an FCBP. Males must refrain from donating blood or sperm during study participation and for 3, 6 or 12 months after the last dose of Tafasitamab, BEN or RTX respectively, whichever is later. In the opinion of the investigator, the patients must: be able to comply with all study-related procedures, medication use, and evaluations be able to understand and give informed consent not be considered to be potentially unreliable and/or not cooperative. EXCLUSION CRITERIA: Patients who have: any other histological type of lymphoma including, e.g., primary mediastinal (thymic) large B-cell lymphoma (PMBL) or Burkitt's lymphoma, primary refractory DLBCL, patients with known double/triple hit DLBCL genetics, CNS lymphoma involvement in present or past medical history Patients who had a major surgery less than 30 days prior to Day 1 dosing Patients who have, within 14 days prior to Day 1 dosing: not discontinued CD20-targeted therapy, chemotherapy, radiotherapy, investigational anticancer therapy or other lymphoma-specific therapy received live vaccines required parenteral antimicrobial therapy for active, intercurrent systemic infections Patients who: in the opinion of the investigator, have not recovered sufficiently from the adverse toxic effects of prior therapies, major surgeries or significant traumatic injuries were previously treated with CD19-targeted therapy or BEN have a history of previous severe allergic reactions to compounds of similar biological or chemical composition to Tafasitamab, RTX, murine proteins or BEN, or the excipients contained in the study drug formulations have undergone ASCT within a period of ≤3 months prior to signing the informed consent form. Patients who have a more distant history of ASCT must exhibit full haematological recovery before enrolment into the study. have undergone previous allogeneic stem cell transplantation concurrently use other anticancer or experimental treatments Prior history of malignancies other than DLBCL, unless the patient has been free of the disease for ≥3 years prior to Screening. Exceptions to the ≥3-year time limit include history of the following: basal cell carcinoma of the skin squamous cell carcinoma of the skin carcinoma in situ of the cervix, breast and bladder f) incidental histological finding of prostate cancer (Tumour/Node/Metastasis [TNM] stage of T1a or T1b) Patients with: positive hepatitis B and/or C serology known seropositivity for or history of active viral infection with HIV evidence of active, severe uncontrolled systemic infections or sepsis a history or evidence of severely immunocompromised state a history or evidence of severe hepatic impairment (total serum bilirubin > 3 mg/dL), jaundice unless secondary to Gilbert's syndrome or documented liver involvement by lymphoma a history or evidence of clinically significant cardiovascular, cerebrovascular, CNS and/or other disease that, in the investigator's opinion, would preclude participation in the study or compromise the patient's ability to give informed consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Tafasitamab and bendamustine<br>Tafasitamab and bendamustine | Drug: Tafasitamab<br>* Tafasitamab: Tafasitamab dose: 12 mg/kg intravenously (IV)<br>Drug: Bendamustine (BEN)<br> <br> * Other names: Levact/Treanda;|
| Active Comparator: Rituximab and bendamustine<br>Rituximab and bendamustine | Drug: Rituximab (RTX)<br>* Rituximab: Dose: 375 mg/m2 IV<br>* Other names: Mab Thera;Drug: Bendamustine (BEN)<br> <br> * Other names: Levact/Treanda;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Progression-free survival (PFS) | To determine the efficacy of a combination of MOR00208 with BEN versus a combination of RTX with BEN in terms of progression-free survival (PFS) in: Adult patients with R-R DLBCL (overall population) A subgroup of adult patients with R-R DLBCL with low baseline peripheral blood NK-cell count (NKCC-low) | From date of randomization until recurrence/disease progression, unacceptable toxicity, death or discontinuation for any other reason, whichever comes first assessed up to 4 yrs | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Objective response rate (ORR) | To determine efficacy | From date of randomization assessed up to 4 yrs | 
| Duration of response (DoR) | To determine efficacy | From date of randomization assessed up to 4 yrs | 
| overall survival (OS) | To determine efficacy | From date of randomization assessed up to 4 yrs | 
| disease control rate (DCR) | To determine efficacy | From date of randomization assessed up to 4 yrs | 
| time to progression (TTP) | To determine efficacy | From date of randomization assessed up to 4 yrs | 
| time to next treatment (TTNT) | To determine efficacy | From date of randomization assessed up to 4 yrs | 
| Number of patients with adverse events | Number of participants with treatment- and non-treatment related adverse events as assessed by CTCAE | assessed up to 4 yrs | 
| quality of life (QoL) | EORTC QLQ-C30 and EQ-5D-5L questionnaires will be used | assessed up to 4 yrs | 
| Number of patients developing Tafasitamab antibodies |  | assessed up to 2 yrs | 
| Maximum Plasma Concentration of Tafasitamab (Cmax) |  | assessed up to 2 yrs | 
| Apparent trough concentration (Cpd) of Tafsitamab |  | assessed up to 2 yrs | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
rituximab, Diffuse Large B-cell Lymphoma, bendamustine, combination therapy, CD19 monoclonal antibody, transplant ineligible